These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16231965)

  • 1. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
    Preskorn SH
    Clin Pharmacokinet; 2005; 44(11):1117-33. PubMed ID: 16231965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
    Mendelowitz AJ
    Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
    Miceli JJ; Wilner KD; Swan SK; Tensfeldt TG
    J Clin Pharmacol; 2005 Jun; 45(6):620-30. PubMed ID: 15901743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
    Brook S; Lucey JV; Gunn KP
    J Clin Psychiatry; 2000 Dec; 61(12):933-41. PubMed ID: 11206599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
    Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
    Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.
    Daniel DG; Zimbroff DL; Swift RH; Harrigan EP
    Int Clin Psychopharmacol; 2004 Jan; 19(1):9-15. PubMed ID: 15101564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
    Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
    J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.
    Barak Y; Mazeh D; Plopski I; Baruch Y
    Am J Geriatr Psychiatry; 2006 Jul; 14(7):629-33. PubMed ID: 16816018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
    Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
    J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.